High throughput screening News and Research

RSS

High-throughput screening (HTS) allows scientists to test thousands of samples at once. These samples can be of a wide variety, and include, but are not limited to, amino acids, chemical compounds or cells.

Scientists discover small molecules that may reduce cellular stress

For many, getting older can unfortunately mean an increased risk of illness from cardiovascular disease to cancer.

5 Oct 2020

Ceftazidime flagged as a potential inhibitor of the SARS-COV-2 virus

After screening more than 3,500 FDA-approved drugs and small molecules, researchers at the Chinese Academy of Sciences found that ceftazidime, an antibiotic approved for use in treating pneumonia, binds to the receptors that the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) binds to in human cells.

17 Sep 2020

Sanford Burnham Prebys receives NIH grant to identify new therapies for mental disorders

Sanford Burnham Prebys Medical Discovery Institute has been awarded a $4.5 million grant from the National Institutes of Health (NIH) to identify new therapies for mental health disorders.

6 Aug 2020

Launching a rapid test for COVID-19

Professor Zhanfeng Cui from the University of Oxford speaks to News-Medical about his research into COVID-19, and how he developed a rapid COVID-19 test.

5 Aug 2020

Novel drug candidate offers a major advance in the treatment for diabetes

The University of Alabama at Birmingham and Southern Research have discovered a new drug candidate that offers a major advance in the treatment for diabetes.

28 Jul 2020

High-quality lab procedures crucial to discovery of effective drugs

In their quest to find new drugs to treat deadly diseases, scientists study millions of molecules at high speed at the same time. Often it is enzymes that are investigated as targets in these 'high-throughput' screenings.

21 Jul 2020

Sanford Burnham Prebys receives CIRM award to advance promising drug candidates for COVID-19

Sanford Burnham Prebys Medical Discovery Institute has received an award from the California Institute for Regenerative Medicine to advance promising drug candidates for COVID-19.

21 Jul 2020

Sphere Fluidics and Heriot-Watt University collaborate to develop next generation droplet generator instrumentation

Sphere Fluidics, a company developing single cell analysis systems underpinned by its patented picodroplet technology, and Heriot-Watt University, a specialist, pioneering Scottish University, today announced they have been awarded a Knowledge Transfer Partnership (KTP) grant from Innovate UK, the UK’s innovation agency.

From Fluidic Sciences and Sphere Bio 20 Jul 2020

Study identifies three novel broad-spectrum SARS-CoV-2 cell entry inhibitors

Researchers from the National Institutes of Health (NIH) and Cornell University in the U.S. just described several new inhibitors of human coronavirus spike proteins by screening a library of approved drugs with SARS-S and MERS-S pseudotyped particle entry assays. Their exciting findings are currently available on the bioRxiv preprint server.

13 Jul 2020

Small molecule drugs binding Mac1 domain of SARS-CoV-2

Now, an intriguing new study out of the University of Wisconsin-Milwaukee reveals that numerous small molecule drugs like the proton pump inhibitors omeprazole and rabeprazole bind the important Mac1 domain on the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus.

8 Jul 2020

Researchers develop bioprinted skin model of cutaneous squamous cell carcinoma

The cover for issue 27 of Oncotarget features "Bimodal imaging examples of control and treated tumors (red) before and after the treatment period," by Browning, et al. and reported that the authors developed a 3-dimensional bioprinted skin model of cutaneous squamous cell carcinoma (cSCC) tumors together with a microscopy assay to test chemotherapeutic effects in tissue.

7 Jul 2020

Cell 'membrane on a chip' could help test potential drug candidates for COVID-19

Researchers have developed a human cell 'membrane on a chip' that allows continuous monitoring of how drugs and infectious agents interact with our cells, and may soon be used to test potential drug candidates for COVID-19.

6 Jul 2020

New approach holds incredible potential for developing new therapeutics

Nearly every drug that is, or has ever been, used was derived from nature -- harnessing compounds created by organisms over eons to fight diseases. But decades ago, biochemists postulated that it might be possible to design a new drug from scratch by linking up amino acids in precise ways.

30 Jun 2020

New assay rapidly tests SARS-CoV-2 neutralization and screens antivirals

Researchers at the University of Texas Medical Branch, Galveston, have developed a new platform that can rapidly test neutralizing antibody activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and perform high-throughput screening of potential antiviral agents.

24 Jun 2020

G42 and Oxford Nanopore co-develop population-scale technology to detect SARS-CoV-2

Group 42 (G42), a leading AI and Cloud Computing company based in the United Arab Emirates, and Oxford Nanopore Technologies, an advanced sequencing technology company based in the United Kingdom, announced today they have developed an unprecedented population-scale technology that rapidly and accurately detects SARS-CoV-2, the virus that causes COVID-19.

10 Jun 2020

New genetic engineering technique sets the stage for advances in medicine and beyond

From bacteria-made insulin that obviates the use of animal pancreases to a better understanding of infectious diseases and improved treatments, genetic engineering of bacteria has redefined modern medicine. Yet, serious limitations remain that hamper| progress in numerous other areas.

30 May 2020

Researchers grow lung organoids from stem cells for Sars-Cov-2 research

A Bochum-based team intends to use organoids from stem cells to study the progression of Sars-CoV-2 infection and to identify antiviral substances.

28 May 2020

New Thermo Scientific Proteome Discoverer 2.5 software strengthens laboratory workflows

Scientists in the life sciences can now benefit from upgrades to a suite of analytical software solutions with new features designed to enhance productivity, confidence and accuracy in numerous fields, including proteomics, food safety and biotherapeutic drug development.

From Thermo Fisher Scientific Inc. 28 May 2020

New Orbitrap Exploris 120 mass spectrometer redefines productivity in small molecule applications

Scientists working across small molecule applications require systems that support extensive, in-depth analysis of multiple complex samples, while simultaneously increasing output and decreasing costs.

From Thermo Fisher Scientific Inc. 28 May 2020

Researchers discover a combination punch to treat drug-resistant infections

McMaster University researchers have discovered a combination punch to treat drug-resistant infections that is showing promise based on testing in mice.

14 May 2020